Thomas Mancini, DPM
Foot Surgery · East Greenwich, RINPI 1265540868
Payments from drug & device makers
Across 81 payments — averaging $38.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$793
- Treace Medical Concepts, Inc.$740
- Organogenesis Inc.$605
- Misonix Inc$201
- Orthofix Medical, Inc.$125
- Amgen$125
- plus $548 from 8 others
What the payments were for
- Travel & lodging$44814%
- Food & beverage$2,68986%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 31 | $793 |
| Treace Medical Concepts, Inc. | 4 | $740 |
| Organogenesis Inc. | 14 | $605 |
| Misonix Inc | 10 | $201 |
| Orthofix Medical, Inc. | 1 | $125 |
| Amgen | 1 | $125 |
| KCI USA, Inc. | 1 | $97 |
| Integra Lifesciences Corporation | 5 | $97 |
| Lifenet Health | 4 | $93 |
| Hydrofera LLC | 3 | $91 |
| Kerecis Limited | 3 | $86 |
| Reapplix Inc. | 2 | $47 |
| Cashflow Solutions, LLC | 1 | $19 |
| Solventum Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lapiplasty System$721
- NOVACHOR$130
- Affinity$130
- PuraPly$128
- Physio-Stim Osteogenesis Stimulator$125
- KRYSTEXXA$125
How this compares
Too few foot surgery providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mupirocin | 38 | $696 |
| Doxycycline Hyclate | 27 | $585 |
| Gabapentin | 24 | $440 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $180 |
| Etodolac | 14 | $144 |
| Cefadroxil | 13 | $126 |
Paid to pharmacies, not to this prescriber.
Other foot surgery in East Greenwich
- James McCormickWakefield$20K
- Eric BuchbaumWakefield$7K
- Louis SimeoneProvidence$1K
- Edmund DosremediosProvidence$1K
- Thomas HuottRiverside$929
- Mark EnanderPawtucket$269
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.